Why Did ACLX Stock Surge 80% In Pre-Market Today?
Synopsis
Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal.
Shares of Arcellx Inc (ACLX) surged nearly 80% in pre-market trading on Monday after Gilead Sciences, Inc. (GILD) announced an agreement to acquire Arcellx in a deal worth around $7.8 billion.
If the pre-market levels hold after the opening bell, ACLX shares will hit an all-time high. Meanwhile, GILD shares traded 1.2% lower in pre-market trading.
Gilead Sciences To Acquire Arcellx
Under the agreement, Gilead will pay $115 per share in cash plus a $5 contingent value right (CVR) tied to future sales milestones. The offer is a 68% premium to Arcellx’s 30-day average share price as of Feb. 20, 2026.
Gilead, which already owns roughly 11.5% of Arcellx, will launch a tender offer for the remaining shares. The deal is expected to close in the second quarter of 2026.
The acquisition is projected to boost Gilead’s earnings per share starting in 2028, following potential U.S. Food and Drug Administration (FDA) approval of anito-cel, a treatment for multiple myeloma, a type of blood cancer.
Get updates to this developing story on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.